Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Link Medicine, a biotechnology company advancing novel approaches for the treatment of neurodegenerative diseases, has obtained $40 million of Series C equity financing to help move its lead preclinical programs into human clinical testing.
Subscribe to our email newsletter
The round was funded by two biotechnology investors – Clarus Ventures and SV Life Sciences.
Adam Rosenberg, CEO of Link Medicine, said: “Link Medicine was established to bring sharp focus to the most pressing need these patients face – for therapies not only designed to alleviate disease symptoms, but to modify the course of the disease. The strong backing of Clarus Ventures and SV Life Sciences both validates the progress we have made to date, and accelerates our path to the clinic.”